Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Tekla Capital Management LLC (CIK 1300336) reported $2.56B across 165 reported positions in its SEC 13F filing for 2023-06-30. Largest positions: AMGN ($136.9M, 5.36%), JNJ ($119.5M, 4.68%), GILD ($118.2M, 4.63%), REGN ($116.0M, 4.54%), VRTX ($111.9M, 4.38%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc. | $136.9M | 5.36% | 616,539 | Added |
| 2 | JNJ | Johnson & Johnson | $119.5M | 4.68% | 721,779 | Hold |
| 3 | GILD | Gilead Sciences, Inc. | $118.2M | 4.63% | 1.5M | Trimmed |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | $116.0M | 4.54% | 161,418 | Added |
| 5 | VRTX | Vertex Pharmaceuticals Inc. | $111.9M | 4.38% | 318,043 | Trimmed |
| 6 | LLY | Eli Lilly and Company | $100.1M | 3.92% | 213,352 | Trimmed |
| 7 | UNH | Unitedhealth Group Inc. | $99.5M | 3.89% | 206,961 | Trimmed |
| 8 | MRK | Merck & Co., Inc. | $84.0M | 3.29% | 728,154 | Added |
| 9 | ABBV | AbbVie Inc. | $73.5M | 2.88% | 545,629 | Added |
| 10 | BIIB | Biogen Inc. | $70.6M | 2.76% | 247,943 | Added |
| 11 | AZN | AstraZeneca PLC | $69.9M | 2.74% | 976,676 | Trimmed |
| 12 | ILMN | Illumina, Inc. | $63.2M | 2.47% | 336,979 | Trimmed |
| 13 | ABT | Abbott Laboratories | $60.2M | 2.36% | 552,455 | Trimmed |
| 14 | PFE | Pfizer Inc. | $59.6M | 2.33% | 1.6M | Trimmed |
| 15 | TMO | Thermo Fisher Scientific Inc. | $51.6M | 2.02% | 98,987 | Added |
| 16 | ELV | Elevance Health, Inc. | $50.7M | 1.98% | 114,070 | Hold |
| 17 | MRNA | Moderna, Inc. | $41.8M | 1.63% | 343,695 | Added |
| 18 | BSX | Boston Scientific Corp. | $35.6M | 1.39% | 657,790 | Added |
| 19 | DHR | Danaher Corp. | $34.3M | 1.34% | 142,813 | Added |
| 20 | MDT | Medtronic plc | $30.3M | 1.19% | 344,417 | Trimmed |
| 21 | IDXX | IDEXX Laboratories, Inc. | $29.4M | 1.15% | 58,595 | Hold |
| 22 | DXCM | Dexcom, Inc. | $29.4M | 1.15% | 228,747 | Hold |
| 23 | BMY | Bristol-Myers Squibb Company | $29.3M | 1.15% | 458,498 | Trimmed |
| 24 | ISRG | Intuitive Surgical, Inc. | $28.7M | 1.12% | 83,980 | Trimmed |
| 25 | ALNY | Alnylam Pharmaceuticals, Inc. | $27.2M | 1.06% | 143,214 | Hold |
Source: SEC Form 13F filings · as of 2023-06-30